A randomized trial of at-home COVID-19 tests, telemedicine, and rapid prescription delivery for immunocompromised individuals.

Background: COVID-19 continues to impose substantial risks to people who are immunocompromised and over 65 years old.

Objective: Using a randomized control trial, we evaluated whether access to at-home COVID-19 tests, telemedicine, and same-day prescription delivery could reduce COVID cases, hospitalizations, and the cost of COVID care for the high-risk populations.

Design: Individuals participated remotely, half (n = 346) receiving the option to access 10 at-home COVID-19 tests per month for themselves and others in their household as well as telemedicine and same-day Paxlovid delivery, and half following their standard testing and treatment practices (n = 325).

The revolution in high-throughput proteomics and AI.

The recent capability to measure thousands of plasma proteins from a tiny blood sample has provided a new dimension of expansive data that can advance our understanding of human health. For example, the company SomaLogic has developed the means to measure more than 10,000 proteins and Thermo Fisher's Olink assays over 5400 proteins from as little as 2 μl. When these rich data are integrated with other layers of information from large patient cohorts, such as the UK Biobank's genetic, health, and lifestyle information from half a million participants, we get new insights about the underpinnings of disease, the aging process, and the potential ability to forecast an individual's health trajectory.